/ print page

Reference

EPO has currently customers from more than 125 scientific institutes, biotech and pharmaceutical companies worldwide.

Selected publications

• Merk,J., Rolff,J., Dorn,C., Leschber,G., and Fichtner,I. (2011).
  Chemoresistance in non-small-cell lung cancer: can multidrug resistance markers predict the response of xenograft lung cancer models to chemotherapy? Eur J Cardiothorac Surg 2011 Mar 17.
  PMID: 21420313 [PubMed - as supplied by publisher]

• Brueckner,B., Rius,M., Markelova,M.R., Fichtner,I., Hals,P.A., Sandvold,M.L., and Lyko,F. (2010).
  Delivery of 5-Azacytidine to Human Cancer Cells by Elaidic Acid Esterification Increases Therapeutic Drug Efficacy.
  Mol Cancer Ther 9, 1256-1264.

• Wenzel,J., Zeisig,R., Haider,W., Habedank,S., and Fichtner,I. (2010).
  Inhibition of pulmonary metastasis in a human MT3 breast cancer xenograft model by dual liposomes preventing intravasal fibrin clot formation.
  Breast Cancer Res Treat 121, 13-22.

• Orthmann,A., Zeisig,R., Koklic,T., Sentjurc,M., Wiesner,B., Lemm,M., and Fichtner,I. (2010).
  Impact of membrane properties on uptake and transcytosis of colloidal nanocarriers across an epithelial cell barrier model.
  J Pharm Sci 99, 2423-2433.

• Hammer,S., Sommer,A., Fichtner,I., Becker,M., Rolff,J., Merk,J., Klar,U., and Hoffmann,J. (2010).
  Comparative profiling of the novel epothilone, sagopilone, in xenografts derived from primary non-small cell lung cancer.
  Clin Cancer Res 16, 1452-1465.

• Wenzel,J., Zeisig,R., and Fichtner,I. (2010).
  Inhibition of metastasis in a murine 4T1 breast cancer model by liposomes preventing tumor cell-platelet interactions.
  Clin Exp Metastasis 27, 25-34.

• Graeser,R., Esser,N., Unger,H., Fichtner,I., Zhu,A., Unger,C., and Kratz,F. (2010).
  INNO-206, the (6-maleimidocaproyl hydrazone derivative of doxorubicin), shows superior antitumor efficacy compared to doxorubicin in different tumor xenograft models and in an orthotopic pancreas carcinoma model.
  Invest New Drugs 28, 14-19.

• Rolff,J., Dorn,C., Merk,J., and Fichtner,I. (2009).
  Response of patient-derived non-small cell lung cancer xenografts to classical and targeted therapies is not related to multidrug resistance markers.
  J Oncol 2009:814140. PMID: 19547715 [PubMed - as supplied by publisher]

• Fritzmann J; Morkel M; Besser D; Budczies J; Kosel F; Brembeck FH; Stein U; Fichtner I; Schlag PM; Birchmeier W (2009)
  A colorectal cancer expression profile that includes transforming growth factor ss inhibitor BAMBI predicts metastatic potential
  Gastroenterology 137 (11): 165-175

• Diaz Miqueli A; Rolff J; Lemm M; Fichtner I; Perez R; Montero E (2009)
  Radiosensitisation of U87MG brain tumours by anti-epidermal growth factor receptor monoclonal antibodies
  British Journal of Cancer 100 (6): 950-958

• Heringer-Walther S; Eckert K; Schumacher SM; Uharek L; Wulf-Goldenberg A; Gembardt F; Fichtner I; Schultheiss HP; Rodgers K; Walther T 2009
  Angiotensin-(1-7) stimulates hematopoietic progenitor cells in vitro and in vivo
  Haematologica 94 (6): 857-860

• Merk J; Rolff J; Becker M; Leschber G; Fichtner I (2009)
  Patient-derived xenografts of non-small-cell lung cancer: a pre-clinical model to evaluate adjuvant chemotherapy?
  European Journal of Cardio-Thoracic Surgery

• Hoffmann J; Fichtner I; Lemm M; Lienau P; Hess-Stumpp H; Rotgeri A; Hofmann B; Klar U (2009)
  Sagopilone crosses the blood-brain barrier in vivo to inhibit brain tumor growth and metastases
  Neuro Oncology 11 (2): 158-166

• Graeser R; Esser N; Unger H; Fichtner I; Zhu A; Unger C; Kratz F (2009)
  INNO-206, the (6-maleimidocaproyl hydrazone derivative of doxorubicin), shows superior antitumor efficacy compared to doxorubicin in different tumor xenograft models and in an orthotopic pancreas carcinoma model
  Investigational New Drugs

• Stein U; Walther W; Arlt F; Schwabe H; Smith J; Fichtner I; Birchmeier W; Schlag PM (2009)
  MACC1, a newly identified key regulator of HGF-MET signaling, predicts colon cancer metastasis
  Nature Medicine 15 (1): 59-67

• Wenzel J; Zeisig R; Haider W; Habedank S; Fichtner I (2009)
  Inhibition of pulmonary metastasis in a human MT3 breast cancer xenograft model by dual liposomes preventing intravasal fibrin clot formation
  Breast Cancer Research and Treatment

• Walther W; Fichtner I; Schlag PM; Stein US (2009)
  Nonviral jet-injection technology for intratumoral in vivo gene transfer of naked DNA
  Methods in Molecular Biology 542: 195-208

• Rolff J; Dorn C; Merk J; Fichtner I (2009)
  Response of patient-derived non-small cell lung cancer xenografts to classical and targeted therapies is not related to multidrug resistance markers
  Journal of Oncology 2009: 814140

• Wenzel J; Zeisig R; Fichtner I (2009)
  Inhibition of breast cancer metastasis by dual liposomes to disturb complex formation
  International Journal of Pharmaceutics 370 (1-2): 121-128

• Fichtner I (2008)
  Praeklinische Daten als Grundlage fuer die Konzeption klinischer Studien [Preclinical data as basis for the design of clinical studies]
  Onkologie 31 (Suppl. 2): 34-38

• Fichtner I, et al. (2008). Establishment of patient-derived non-small cell lung cancer xenografts as models for the identification of predictive biomarkers. Clin Cancer Res 14: 6456-6468.

• Stein U; Walther W; Stege A; Kaszubiak A; Fichtner I; Lage H (2008)
  Complete in vivo reversal of the multidrug resistance phenotype by jet-injection of anti-MDR1 short hairpin RNA-encoding plasmid DNA
  Molecular Therapy 16 (1): 178-186

• Wulf-Goldenberg A, et al. (2008). Cytokine-pretreatment of CD34+ cord blood stem cells in vitro reduces long-term cell engraftment in NOD/SCID mice. Eur J Cell Biol 87: 69-80.

• Behrens D, et al. (2007). Loss of Tumorigenicity
  of stably ERβ-transfected MCF-7 breast cancer cells. Mol Cell Endocrinol 274: 19-29.

• Behrens D, et al. (2007). The mTOR pathway inhibitor RAD001 (everolimus) is highly efficacious in tamoxifen-sensitive and -resistant breast cancer xenografts. Targeted Oncology 2: 135-144.

• Zeisig R, et al. (2007). Increase in fluidity in the membrane of MT3 breast cancer cells correlates with enhanced cell adhesion in vitro and increased lung metastasis in NOD/SCID mice. Arch Biochem Biophys 459: 98-106.

• Fichtner I, et al. (2006). Antitumor activity of titanocene Y in xenografted Caki-1 tumors in mice. Anti-Cancer Drugs 17:333-336.

• Einsiedel HG, et al. (2006). Histone deacetylase inhibitors have antitumor activity in two NOD/SCID mouse models of B-cell precursor childhood acute lymphoblastic leukemia. Leukemia 20: 1435-1436.

• Schanzer JM, et al. (2006). Antitumor activity of a dual cytokine/single-chain antibody fusion protein for simultaneous delivery of GM-CSF and IL-2 to Ep-CAM expressing tumor cells. J Immunother 29: 477-488.

• Shalapour S, et al. (2006). The thalidomide analogue, CC-4047, induces apoptosis signaling and growth arrest in childhood acute lymphoblastic leukemia cells in vitro and in vivo. Clin Cancer Res 12: 5526-5532.

• Becker M, et al. (2005). Distinct gene expression patterns in a tamoxifen-sensitive human mammary carcinoma xenograft and its tamoxifen-resistant subline MaCa 3366/TAM. Mol Cancer Thera 4: 151-168.

• Schlereth et al. (2005). Eradication of tumors from a human colon cancer cell line and from ovarian cancer metastases in immunodeficient mice by a single-chain Ep-CAM-/CD3-bispecific antibody construct. Cancer Res 65: 2882-2889.

• Fichtner I, et al. (2004). Anticancer drug response and expression of molecular markers in early-passage xenotransplanted colon carcinomas. Eur J Cancer 40: 298-307.

• Keil C, et al. (2005) Effect of surface modified liposomes on the aggregation of platelets and tumor cells. Thromb Haemost 94: 404-411.

• Zeisig R, et al. (2004). Effect of sialyl Lewis X-glycoliposomes on the inhibition of E-selectin mediated tumor cell adhesion in vitro. Biochim Biophys Acta 1660: 31-40.

• Fichtner I, et al. (2004). In vivo models for endocrine-dependent breast carcinomas: special considerations of clinical relevance. Eur J Cancer 40:845-851.

• Zeisig R, et al. (2004). Liposomal 4-hydroxy-tamoxifen: effect on cellular uptake and resulting cytotoxicity in drug resistant breast cancer cells in vitro. Breast Cancer Res Treat 87: 245-254.

• Fichtner I, et al. (2004). Anticancer drug response and expression of molecular markers in early-passage xenotransplanted colon carcinomas. Eur J Cancer 40: 298-307.

• Fichtner I, et al. (2004). In vivo models for endocrine tumors: Special considerations. Eur J Cancer 40: 845-851.

• Fichtner I, et al. (2003). Animal experiments - an essential component for the development of liposomal anticancer agents. J Liposome Res 13: 9-15.

• Zeisig R, et al. (2003). Lipoplexes with alkylphospholipid as new helper lipid for efficient in vitro and in vivo gene transfer in tumor therapy. Cancer Gene Therapy 10: 302-311.

• Fichtner I, et al. (2003). Chemo- and radiation sensitivity of xenografted acute lymphoblastic leukemias - correlation to the expression of multidrug resistance proteins. Anticancer Res 23: 2657-2664.

• Dreier T, et al. (2003) T cell costimulus-independent and very efficacious inhibition of tumor growth in mice bearing subcutaneous or leukemic human B cell lymphoma xenografts by a CD19-/CD3- bispecific single-chain antibody construct1. J Immunol 170: 4397-4402.

• Becker M, et al. (2002). Sensitive PCR method for the detection and real-time quantification of human cells in xenotransplantation systems. Brit J Cancer 87: 1328-1335.

• Naundorf H, et al. (2000). Development and characterization of a tamoxifen-resistant breast carcinoma xenograft. Brit J Cancer 82: 1844-1850.

• Goan SR, et al. (2000). Donor stromal cells from human blood engraft in NOD/SCID mice. Blood 96: 3971-3978.

• Borgmann A, et al. (2000). Childhood ALL blasts retain phenotypic and genotypic characteristics upon long-term serial passage in NOD/SCID mice. Pediatr Hematol Oncol 17: 635-650.

• Hoffmann J, et al. (1999). Anticancer drug sensitivity and expression of multidrug resistance markers in early passage human sarcomas. Clin Cancer Res 5: 2198-2204.

• Stein U, et al. (1997). Development and characterisation of novel human multidrug resistant mammary carcinoma lines in vitro and in vivo. Int J Cancer 72: 885-891.

Top